University of Colorado Cancer Center Associate Director of Clinical Research, Christopher Lieu, MD, is bringing his wealth of expertise and dedication to a new role as the Vice Chair of the National Comprehensive Cancer Network (NCCN).
Press Releases Equity Diversity and Inclusion Leadership
The University of Colorado Cancer Center is doubling down on its diversity, equity, inclusion, and access (DEIA) efforts in 2023, adding an associate director and deputy associate director of DEIA to its leadership team.
Diana Cittelly, PhD, a longtime University of Colorado Cancer Center member and a researcher on cancer that spreads to the brain, has taken on a new role at the CU Cancer Center.
The Protocol Review and Monitoring System (PRMS) in the University of Colorado Cancer Center’s Clinical Trials Office is under new leadership.
Community Cancer Magazine Equity Diversity and Inclusion ColoradoSPH at CU Anschutz Leadership
Two important numbers to keep in mind are that 50.5% of the U.S. population is female, and that cancer will account for more than 606,000 deaths in the United States this year, making it the second-leading cause of death.
Press Releases Community ColoradoSPH at CU Anschutz Leadership
Jan Lowery, PhD, MPH, who started her career as a researcher at the University of Colorado Cancer Center, returned September 1 as assistant director for dissemination and implementation for the Office of Community Outreach and Engagement at the CU Cancer Center. In her new role, Lowery will lead efforts to develop, conduct, and disseminate implementation-focused projects in cancer prevention, early detection, and survivorship.
Diversity Clinical Research Inclusion Leadership
As lead investigator or sub-investigator on numerous clinical trials at the University of Colorado Cancer Center — many of them investigating new treatments for head and neck cancer — Jessica McDermott, MD, has been instrumental in improving access to cancer clinical trials for patients from medically underserved communities.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Megan Palffy
